Author:
Diekstra M H,Belaustegui A,Swen J J,Boven E,Castellano D,Gelderblom H,Mathijssen R H,García-Donas J,Rodríguez-Antona C,Rini B I,Guchelaar H-J
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Reference21 articles.
1. van der Veldt A, Eechoute K, Gelderblom H, Gietema J, Guchelaar H-J, van Erp N et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011; 17: 620–629.
2. van Erp N, Eechoute K, van der Veldt A, Haanen J, Reyners A, Mathijssen R et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009; 27: 4406–4412.
3. Garcia-Donas J, Esteban E, Leandro-Garcia L, Castellano D, del Alba A, Climent M et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011; 12: 1143–1150.
4. Eechoute K, van der Veldt A, Oosting S, Kappers M, Wessels J, Gelderblom H et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther 2012; 92: 503–510.
5. Kim J, Vaziri S, Rini B, Elson P, Garcia J, Wirka R et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012; 118: 1946–1954.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献